This annual training course, considered by many experts as one of the pillars of medical training in pharmacovigilance, focuses on how to use medical knowledge in the diagnosis and management of selected Adverse Drug Reactions (ADRs). ADRs of the main systems/organs will be presented and explained by experts in their medical domain in order to provide practical clues to understand and manage the serious reactions in clinical trials a well as in post authorisation.
A medical approach is needed for the identification, labelling and understanding of ADR mechanisms. It can also help assess the probability that a medicinal product may have played a role in the occurrence of an adverse event. This is particularly useful for the first 2 or 3 cases of serious reactions occurring during clinical trials when important decisions must be taken regarding a new drug under development.
The medical approach presented in this training course will take into consideration the conclusions of international or national consensus meetings on adverse drug reactions.
This course can be complemented by Drug-Induced Liver Injury (DILI): Diagnosis and Management, scheduled in the same venue directly after this course.
Gaby L. Danan, MD, PhD • Pharmacovigilance Expert